BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867-872. [PMID: 8598364 DOI: 10.1016/0360-3016(95)02134-5] [Cited by in Crossref: 228] [Cited by in F6Publishing: 199] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Hazard LJ, Sause WT; Radiation Therapy Oncology Group. The treatment of unresectable, locally advanced non-small-cell lung cancer: a radiation therapy perspective with an emphasis on the trials of the Radiation Therapy Oncology Group. Clin Lung Cancer 2002;3:191-9. [PMID: 14662042 DOI: 10.3816/clc.2002.n.002] [Reference Citation Analysis]
2 Aguilar-ponce J, Granados-garcía M, Villavicencio V, Poitevin-chacón A, Green D, Dueñas-gonzález A, Herrera-gómez Á, Luna-ortiz K, Alvarado A, Martínez-said H, Castillo-henkel C, Segura-pacheco B, De la Garza J. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology 2004;15:301-6. [DOI: 10.1093/annonc/mdh071] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
3 Cengiz M, Zorlu F, Yalcin S, Gurkaynak M, Atahan IL, Gullu IH. Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Med Oncol 2007;24:239-43. [DOI: 10.1007/bf02698046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Tuli R, Surmak AJ, Reyes J, Armour M, Hacker-Prietz A, Wong J, DeWeese TL, Herman JM. Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888. Transl Oncol. 2014; Epub ahead of print. [PMID: 24836647 DOI: 10.1016/j.tranon.2014.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
5 Fasih A, Elbaz HA, Hüttemann M, Konski AA, Zielske SP. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res 2014;182:50-9. [PMID: 24909911 DOI: 10.1667/RR13568.1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
6 Harada H, Shibuya K, Hiraoka M. Combinations of Antimetabolites and Ionizing Radiation. In: Brown JM, Mehta MP, Nieder C, editors. Multimodal Concepts for Integration of Cytotoxic Drugs. Berlin/Heidelberg: Springer-Verlag; 2006. pp. 19-34. [DOI: 10.1007/3-540-35662-2_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Rübe CE, Wilfert F, Uthe D, König J, Liu L, Schuck A, Willich N, Remberger K, Rübe C. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol 2004;72:231-41. [PMID: 15297141 DOI: 10.1016/j.radonc.2004.05.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
8 Horev-drori G, Cooks T, Bittan H, Lazarov E, Schmidt M, Arazi L, Efrati M, Kelson I, Keisari Y. Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224Radium-loaded wires releasing alpha-emitting atoms. Translational Research 2012;159:32-41. [DOI: 10.1016/j.trsl.2011.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
9 Huang P, Chao Y, Li C, Lee R, Chi K, Shiau C, Wang L, Yen S. Efficacy and Factors Affecting Outcome of Gemcitabine Concurrent Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2009;73:159-65. [DOI: 10.1016/j.ijrobp.2008.04.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
10 Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Van Bockstaele DR, Vermeulen K, Lenjou M, de Pooter CM, Vermorken JB, Lardon F. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 2003;57:1075-83. [PMID: 14575839 DOI: 10.1016/s0360-3016(03)01443-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
11 Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer. Ann Surg Oncol 2008;15:3521-31. [DOI: 10.1245/s10434-008-0152-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
12 Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158. [PMID: 16418882 DOI: 10.1245/aso.2006.03.039] [Cited by in Crossref: 185] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
13 Huang J, Robertson JM, Margolis J, Balaraman S, Gustafson G, Khilanani P, Nadeau L, Jury R, Mcintosh B. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiotherapy and Oncology 2011;99:114-9. [DOI: 10.1016/j.radonc.2011.05.038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
14 McMullen KP, Blackstock AW. Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer 2002;2:24-30. [PMID: 12453333 DOI: 10.3816/CCC.2002.n.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Pauwels B, Wouters A, Peeters M, Vermorken JB, Lardon F. Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. Future Oncol. 2010;6:1485-1496. [PMID: 20919831 DOI: 10.2217/fon.10.104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
16 Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-50. [PMID: 17827452 DOI: 10.1200/JCO.2007.11.5287] [Cited by in Crossref: 75] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
17 Zhang M, Boyer M, Rivory L, Hong A, Clarke S, Stevens G, Fife K. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non–small-cell lung cancer cells. International Journal of Radiation Oncology*Biology*Physics 2004;58:353-60. [DOI: 10.1016/j.ijrobp.2003.09.032] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
18 Boucher PD, Shewach DS. In Vitro and in Vivo Enhancement of Ganciclovir-Mediated Bystander Cytotoxicity with Gemcitabine. Molecular Therapy 2005;12:1064-71. [DOI: 10.1016/j.ymthe.2005.07.643] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
19 Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105-4112. [PMID: 21969502 DOI: 10.1200/jco.2011.34.8904] [Cited by in Crossref: 517] [Cited by in F6Publishing: 235] [Article Influence: 47.0] [Reference Citation Analysis]
20 Khan A, Pitsinis V, Mudan S. Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: Challenging the boundaries. World J Gastroenterol 2007; 13(47): 6433-6435 [PMID: 18081235 DOI: 10.3748/wjg.v13.i47.6433] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010;70:4972-4981. [PMID: 20501833 DOI: 10.1158/0008-5472.can-09-3573] [Cited by in Crossref: 211] [Cited by in F6Publishing: 130] [Article Influence: 17.6] [Reference Citation Analysis]
22 Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88-95. [PMID: 19561477 DOI: 10.1097/sla.0b013e3181ad65cc] [Cited by in Crossref: 93] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
23 Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801-808. [PMID: 17379445 DOI: 10.1016/j.ijrobp.2006.12.053] [Cited by in Crossref: 159] [Cited by in F6Publishing: 138] [Article Influence: 10.6] [Reference Citation Analysis]
24 Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-8. [PMID: 12377962 DOI: 10.1200/JCO.2002.03.054] [Cited by in Crossref: 298] [Cited by in F6Publishing: 52] [Article Influence: 14.9] [Reference Citation Analysis]
25 Miller AR, Robinson EK, Lee JE, Pisters PW, Chiao PJ, Lenzi R, Abbruzzese JL, Evans DB. Neoadjuvant Chemoradiation for Adenocarcinoma of the Pancreas. Surgical Oncology Clinics of North America 1998;7:183-97. [DOI: 10.1016/s1055-3207(18)30293-x] [Cited by in Crossref: 15] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ryan DP, Grossbard ML. Pancreatic Cancer: Local Success and Distant Failure. The Oncologist 1998;3:178-88. [DOI: 10.1634/theoncologist.3-3-178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Coucke PA, Cottin E, Decosterd LA. Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2'-deoxy-(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro. Acta Oncol 2007;46:612-20. [PMID: 17562437 DOI: 10.1080/02841860601137389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
28 Szatmári T, Huszty G, Désaknai S, Spasokoukotskaja T, Sasvári-székely M, Staub M, Ésik O, Sáfrány G, Lumniczky K. Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas. Cancer Gene Ther 2008;15:154-64. [DOI: 10.1038/sj.cgt.7701115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
29 Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99:108-113. [PMID: 21571383 DOI: 10.1016/j.radonc.2011.04.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
30 Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54:447-72. [PMID: 9279506 DOI: 10.2165/00003495-199754030-00009] [Cited by in Crossref: 165] [Cited by in F6Publishing: 146] [Article Influence: 6.6] [Reference Citation Analysis]
31 Osti MF, Costa AM, Bianciardi F, De Nicolò M, Donato V, Silecchia G, Enrici RM. Concomitant Radiotherapy with Protracted 5-fluorouracil Infusion in Locally Advanced Carcinoma of the Pancreas: A Phase Ii Study. Tumori 2001;87:398-401. [DOI: 10.1177/030089160108700609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Mori S, Shinoto M, Yamada S. Four-dimensional treatment planning in layer-stacking boost irradiation for carbon-ion pancreatic therapy. Radiotherapy and Oncology 2014;111:258-63. [DOI: 10.1016/j.radonc.2014.02.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
33 Steward WP. Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 1998;78 Suppl 3:15-9. [PMID: 9717986 DOI: 10.1038/bjc.1998.749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
34 Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG; Eastern Cooperative Oncology Group. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005;62:1345-50. [PMID: 16029791 DOI: 10.1016/j.ijrobp.2004.12.074] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 6.1] [Reference Citation Analysis]
35 Hirata T, Teshima T, Nishiyama K, Ogawa K, Otani K, Kawaguchi Y, Konishi K, Tomita Y, Takahashi H, Ohigashi H, Ishikawa O. Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses. Radiother Oncol 2015;114:122-7. [PMID: 25614389 DOI: 10.1016/j.radonc.2015.01.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
36 Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, Shi J, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2020;106:124-33. [PMID: 31494181 DOI: 10.1016/j.ijrobp.2019.08.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
37 Li Y, Gu WJ, Liu HL. Induction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA. Dig Dis Sci 2012;57:2072-8. [PMID: 22573342 DOI: 10.1007/s10620-012-2132-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7:472-8. [PMID: 24956939 DOI: 10.1016/j.tranon.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:2692-700. [PMID: 23720019 DOI: 10.1002/cncr.28117] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 13.2] [Reference Citation Analysis]
40 Mose S, Karapetian M, Jüling-pohlit L, Taborski B, Ramm U, Damrau M, Rahn A, Böttcher HD. VerstÄrkung der radiotherapeutischen wirkung auf HeLa-Zellen durch gemcitabine. Strahlenther Onkol 1999;175:78-83. [DOI: 10.1007/bf02753847] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Tse RV, Dawson LA, Wei A, Moore M. Neoadjuvant treatment for pancreatic cancer—A review. Critical Reviews in Oncology/Hematology 2008;65:263-74. [DOI: 10.1016/j.critrevonc.2007.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
42 Robertson JM, Margolis J, Jury RP, Balaraman S, Cotant MB, Ballouz S, Boxwala IG, Jaiyesimi IA, Nadeau L, Hardy-Carlson M, Marvin KS, Wallace M, Ye H. Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;82:e187-92. [PMID: 21549514 DOI: 10.1016/j.ijrobp.2010.08.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-4456. [PMID: 20837948 DOI: 10.1200/JCO.2010. 30.3446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Morgan MA, Meirovitz A, Davis MA, Kollar LE, Hassan MC, Lawrence TS. Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. Transl Oncol 2008;1:36-43. [PMID: 18607506 DOI: 10.1593/tlo.07106] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
45 Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). International Journal of Radiation Oncology*Biology*Physics 2000;47:785-91. [DOI: 10.1016/s0360-3016(00)00447-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
46 Castro Kreder N, Van Bree C, Franken NAP, Haveman J. Effects of Gemcitabine on Cell Survival and Chromosome Aberrations after Pulsed Low Dose-rate Irradiation. JRR 2004;45:111-8. [DOI: 10.1269/jrr.45.111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
47 Xiong HQ, Abbruzzese JL. Adjuvant therapy for pancreatic cancer: current status and future directions. Surg Oncol Clin N Am 2004;13:737-49, xi. [PMID: 15350945 DOI: 10.1016/j.soc.2004.06.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Okunieff P, Meyn RE, Teicher BA, Thomas CR, Gaspar LE, Raben D, Giri S, Lavey RS, Turrisi AT, Swanson GP, Smalley SR. Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. American Journal of Clinical Oncology 2003;26:522-9. [DOI: 10.1097/01.coc.0000092253.71406.2b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
49 Azria D, Riou O, Rebillard X, Thezenas S, Thuret R, Fenoglietto P, Pouessel D, Culine S. Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of a Phase 1 Trial. International Journal of Radiation Oncology*Biology*Physics 2014;88:853-9. [DOI: 10.1016/j.ijrobp.2013.11.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
50 Mcginn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS. Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer. JCO 2001;19:4202-8. [DOI: 10.1200/jco.2001.19.22.4202] [Cited by in Crossref: 245] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
51 Springett GM, Hoffe SE. Borderline resectable pancreatic cancer: on the edge of survival. Cancer Control. 2008;15:295-307. [PMID: 18813197 DOI: 10.1177/107327480801500404] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
52 Wilkowski R, Thoma M, Dühmke E, Rau HG, Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. International Journal of Radiation Oncology*Biology*Physics 2004;58:768-72. [DOI: 10.1016/j.ijrobp.2003.07.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, Levine E, Blackstock AW. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 2005;28:345-50. [PMID: 16062075 DOI: 10.1097/01.coc.0000159559.42311.c5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
54 Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH. Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys 2003;57:553-62. [PMID: 12957269 DOI: 10.1016/s0360-3016(03)00503-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
55 Ben-josef E, Lawrence TS. The importance of local control in pancreatic cancer. Nat Rev Clin Oncol 2012;9:9-10. [DOI: 10.1038/nrclinonc.2011.182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
56 Valentini V, Calvo F, Reni M, Krempien R, Sedlmayer F, Buchler MW, Di Carlo V, Doglietto GB, Fastner G, Garcia-Sabrido JL, Mattiucci G, Morganti AG, Passoni P, Roeder F, D'Agostino GR. Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol 2009;91:54-9. [PMID: 18762346 DOI: 10.1016/j.radonc.2008.07.020] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
57 Ali EM, Abdelraheem AG. Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Head Neck Oncol 2011;3:48. [PMID: 22085617 DOI: 10.1186/1758-3284-3-48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
58 Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2001;51:974-981. [PMID: 11704320 DOI: 10.1016/S0360-3016(01)01737-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
59 Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, Seong JS, Lee WJ, Song SY. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004;60:1494-501. [PMID: 15590180 DOI: 10.1016/j.ijrobp.2004.05.061] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
60 Belli C, Cereda S, Anand S, Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev. 2013;39:518-524. [PMID: 23122322 DOI: 10.1016/j.ctrv.2012.09.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
61 Morgan M, El Shaikh MA, Abu-Isa E, Davis MA, Lawrence TS. Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model. Transl Oncol 2008;1:44-9. [PMID: 18607504 DOI: 10.1593/tlo.07118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
62 Ben-Josef E, Lawrence TS. Chemoradiotherapy for unresectable pancreatic cancer. Int J Clin Oncol 2008;13:121-6. [PMID: 18463955 DOI: 10.1007/s10147-007-0763-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
63 Blackstock A, Lesser GJ, Fletcher-steede J, Case L, Tucker RW, Russo SM, White DR, Miller A. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non–small-cell lung cancer. International Journal of Radiation Oncology*Biology*Physics 2001;51:1281-9. [DOI: 10.1016/s0360-3016(01)01732-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
64 Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9. [PMID: 20134315 DOI: 10.1097/SLA.0b013e3181cc90a3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
65 Hindriksen S, Bijlsma MF. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) 2012;4:989-1035. [PMID: 24213498 DOI: 10.3390/cancers4040989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
66 Im MM, Flanagan SA, Ackroyd JJ, Shewach DS. Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine. Radiat Res 2015;183:114-23. [PMID: 25564718 DOI: 10.1667/RR13807.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ryan DP, Willett CG. Management of locally advanced adenocarcinoma of the pancreas. Hematology/Oncology Clinics of North America 2002;16:95-103. [DOI: 10.1016/s0889-8588(01)00009-0] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
68 Demols A, Peeters M, Polus M, Honoré P, Boterberg T, Gay F, Closon MT, Van Houtte P, Closset J, Van Laethem JL. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys 2005;62:1351-6. [PMID: 16029792 DOI: 10.1016/j.ijrobp.2005.01.043] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
69 Ch’ang H, Lin Y, Wang H, Chiu Y, Chang M, Hsu C, Tien Y, Chen J, Hsieh R, Lin P, Shan Y, Cheng A, Chang J, Whang-peng J, Hwang T, Chen L. Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. International Journal of Radiation Oncology*Biology*Physics 2011;81:e749-57. [DOI: 10.1016/j.ijrobp.2010.10.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
70 Frederick WAI, Wolff RA, Crane CH, Lee JE, Pisters PWT, Evans DB. Preoperative (Neoadjuvant) Therapy for Resectable Adenocarcinoma of the Pancreas. In: Evans DB, Pisters PWT, Abbruzzese JL, editors. Pancreatic Cancer. New York: Springer-Verlag; 2002. pp. 243-54. [DOI: 10.1007/0-387-21600-6_21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 N Kalimuthu S, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R, Chetty R. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. J Clin Pathol 2017;70:237-43. [PMID: 27681847 DOI: 10.1136/jclinpath-2016-203947] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
72 Viani GA, Afonso SL, Tavares VC, Bernardes da Silva LG, Stefano EJ. Weekly Gemcitabine and Cisplatin in Combination With Radiotherapy in Patients With Locally Advanced Head-and-Neck Cancer: Phase I Study. International Journal of Radiation Oncology*Biology*Physics 2011;81:e231-5. [DOI: 10.1016/j.ijrobp.2011.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
73 Chakravarthy A, Abrams RA. Radiation therapy and 5-fluorouracil in pancreatic cancer. Seminars in Radiation Oncology 1997;7:291-9. [DOI: 10.1016/s1053-4296(97)80028-8] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
74 Sandblom V, Spetz J, Shubbar E, Montelius M, Ståhl I, Swanpalmer J, Nilsson O, Forssell-Aronsson E. Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. PLoS One 2019;14:e0225260. [PMID: 31725814 DOI: 10.1371/journal.pone.0225260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Bump EA, Hoffman SJ, Foye WO. Radiosensitizers and Radioprotective Agents. Burger's Medicinal Chemistry and Drug Discovery. Wiley; 2003. pp. 151-214. [DOI: 10.1002/0471266949.bmc077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Sarkisjan D, van den Berg J, Smit E, Lee YB, Kim DJ, Peters GJ. The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines. Nucleosides Nucleotides Nucleic Acids 2016;35:619-30. [PMID: 27906620 DOI: 10.1080/15257770.2016.1216565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-20. [DOI: 10.1002/(sici)1097-0142(19970415)79:8<1516::aid-cncr11>3.0.co;2-0] [Cited by in Crossref: 86] [Article Influence: 3.4] [Reference Citation Analysis]
78 Rosier J, Bruniaux M, Husson B, Octave-prignot M, Beauduin M, Grégoire V. Role of 2′-2′ difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas. Radiotherapy and Oncology 2004;70:55-61. [DOI: 10.1016/j.radonc.2003.10.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
79 Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003;97:1346-52. [PMID: 12599244 DOI: 10.1002/cncr.11165] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
80 Salem SD, Abou-tarboush FM, Saeed NM, Al-qadasi WD, Farah MA, Al-buhairi M, Al-harbi N, Alhazza I, Alsbeih G. Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines. Gene 2012;498:300-7. [DOI: 10.1016/j.gene.2012.01.099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hartley M, Ghaneh P, Sutton R, Neoptolemos JP, Magee CJ. The role of adjuvant therapy for pancreatic cancer. Expert Opinion on Investigational Drugs 2005;11:87-107. [DOI: 10.1517/13543784.11.1.87] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
82 Desai SP, Ben-josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti LM, Lawrence TS, Zalupski MM. Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer. JCO 2007;25:4587-92. [DOI: 10.1200/jco.2007.12.0592] [Cited by in Crossref: 45] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
83 Shin JY, Lim HT, Minai-Tehrani A, Noh MS, Kim JE, Kim JH, Jiang HL, Arote R, Kim DY, Chae C, Lee KH, Kim MS, Cho MH. Aerosol delivery of beclin1 enhanced the anti-tumor effect of radiation in the lungs of K-rasLA1 mice. J Radiat Res 2012;53:506-15. [PMID: 22843615 DOI: 10.1093/jrr/rrs005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
84 Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 2016;39:1-7. [DOI: 10.1097/coc.0000000000000003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
85 Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle JM, Le Pape A. Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One 2012;7:e52653. [PMID: 23300736 DOI: 10.1371/journal.pone.0052653] [Cited by in Crossref: 155] [Cited by in F6Publishing: 126] [Article Influence: 15.5] [Reference Citation Analysis]
86 Fietkau R. Concomitant radiochemotherapy of advanced non-small-cell lung cancer. Lung Cancer 2001;33 Suppl 1:S65-76. [PMID: 11576710 DOI: 10.1016/s0169-5002(01)00305-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs. 2000;18:43-56. [PMID: 10830140 DOI: 10.1023/A: 1006383831045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Wilkowski R, Wolf M, Heinemann V. Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res. 2008;177:79-93. [PMID: 18084950 DOI: 10.1007/978-3-540-71279-4_10] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
89 Roy R, Maraveyas A. Chemoradiation in pancreatic adenocarcinoma: a literature review. Oncologist. 2010;15:259-269. [PMID: 20203172 DOI: 10.1634/theoncologist.2009-0272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
90 Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined Modality Therapy of Gemcitabine and Radiation. The Oncologist 2005;10:34-51. [DOI: 10.1634/theoncologist.10-1-34] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 5.9] [Reference Citation Analysis]
91 Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002;86:1551-4. [PMID: 12085203 DOI: 10.1038/sj.bjc.6600256] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
92 Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. International Journal of Radiation Oncology*Biology*Physics 2003;57:1310-6. [DOI: 10.1016/s0360-3016(03)00763-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
93 Valentini AM, Armentano R, Pirrelli M, Caruso ML. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: The state of the art. Cancer Treatment Reviews 2006;32:607-18. [DOI: 10.1016/j.ctrv.2006.08.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
94 Buchsbaum DJ, Bonner JA, Grizzle WE, Stackhouse MA, Carpenter M, Hicklin DJ, Bohlen P, Raisch KP. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54:1180-93. [PMID: 12419447 DOI: 10.1016/s0360-3016(02)03788-4] [Cited by in Crossref: 84] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
95 Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2013;7:308-322. [PMID: 23148997 DOI: 10.1016/j.molonc.2012.10.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
96 Xu Y, Zhang Y, Wu Z, Wang D, Wu W, Kuang T, Lou W. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Jpn J Clin Oncol 2020;50:679-87. [PMID: 32372083 DOI: 10.1093/jjco/hyaa035] [Reference Citation Analysis]
97 Landau E, Kalnicki S. The Evolving Role of Radiation in Pancreatic Cancer. Surg Clin North Am 2018;98:113-25. [PMID: 29191268 DOI: 10.1016/j.suc.2017.09.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
98 Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006;95:260-5. [PMID: 16868545 DOI: 10.1038/sj.bjc.6603270] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
99 Stauder MC, Miller RC. Stereotactic Body Radiation Therapy (SBRT) for Unresectable Pancreatic Carcinoma. Cancers (Basel) 2010;2:1565-75. [PMID: 24281173 DOI: 10.3390/cancers2031565] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
100 Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys. 2010;77:1426-1432. [PMID: 20056351 DOI: 10.1016/j.ijrobp.2009.06.053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
101 Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002;38:223-30. [PMID: 11803139 DOI: 10.1016/s0959-8049(01)00360-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
102 Sukari A, Al-Hajeili M, Salem M, Heilbrun L, Smith D, Yoo G, Jacobs JR, Lin HS, Kucuk O. Biweekly gemcitabine and paclitaxel in patients with relapsed or metastatic squamous cell carcinoma of the head and neck. Avicenna J Med 2015;5:36-41. [PMID: 25878965 DOI: 10.4103/2231-0770.154195] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
103 Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB. Eastern Cooperative Oncology Group Phase I Trial of Protracted Venous Infusion Fluorouracil Plus Weekly Gemcitabine With Concurrent Radiation Therapy in Patients With Locally Advanced Pancreas Cancer: A Regimen With Unexpected Early Toxicity. JCO 2000;18:3384-9. [DOI: 10.1200/jco.2000.18.19.3384] [Cited by in Crossref: 92] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
104 Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Kamphuis JA, De Pooter CM, Peters GJ, Lardon F, Vermorken JB. The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines. BMC Cancer 2006;6:142. [PMID: 16734894 DOI: 10.1186/1471-2407-6-142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
105 Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28:1011-1018. [PMID: 15573257 DOI: 10.1007/s00268-004-7338-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
106 LeBlanc AK, LaDue TA, Turrel JM, Klein MK. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466-70. [PMID: 15487572 DOI: 10.1111/j.1740-8261.2004.04080.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
107 Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003;57:98-104. [PMID: 12909221 DOI: 10.1016/s0360-3016(03)00435-8] [Cited by in Crossref: 147] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
108 Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, Ozkan L, Evrensel T, Kaya E, Manavoglu O. Phase II Study of Induction Chemotherapy with Gemcitabine plus 5-Fluorouracil Followed by Gemcitabine-Based Concurrent Chemoradiotherapy for Unresectable Locally Advanced Pancreatic Cancer. Tumori 2006;92:481-6. [DOI: 10.1177/030089160609200603] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
109 Molls M, Nieder C, Belka C, Norum J. Quantitative Cell Kill of Radio- and Chemotherapy. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. Berlin: Springer Berlin Heidelberg; 2009. pp. 169-90. [DOI: 10.1007/978-3-540-74386-6_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer M, Collette L, Budach V, Lutz M, Van Cutsem E, Haustermans K. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-4456. [PMID: 20837948 DOI: 10.1200/jco.2010.30.3446] [Cited by in Crossref: 184] [Cited by in F6Publishing: 73] [Article Influence: 15.3] [Reference Citation Analysis]
111 Supiot S, Thillays F, Rio E, Gouard S, Morgenstern A, Bruchertseifer F, Mahé M, Chatal J, Davodeau F, Chérel M. Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation. Radiotherapy and Oncology 2007;83:97-101. [DOI: 10.1016/j.radonc.2007.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
112 Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009;7:43. [PMID: 19519883 DOI: 10.1186/1479-5876-7-43] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
113 Son SH, Song JH, Choi BO, Kang YN, Lee MA, Kang KM, Jang HS. The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer. Radiat Oncol 2012;7:203. [PMID: 23216796 DOI: 10.1186/1748-717X-7-203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
114 van Bree C, Rodermond H, Leen R, Medema J, van Kuilenburg A. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells. Br J Cancer 2008;98:1226-33. [PMID: 18349845 DOI: 10.1038/sj.bjc.6604287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
115 Caffo O, Veccia A, Fellin G, Russo L, Mussari S, Galligioni E. Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature. Crit Rev Oncol Hematol 2013;86:176-90. [PMID: 23088957 DOI: 10.1016/j.critrevonc.2012.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
116 Shewach DS, Lawrence TS. Nucleoside Radiosensitizers. In: Peters GJ, editor. Deoxynucleoside Analogs In Cancer Therapy. Totowa: Humana Press; 2007. pp. 289-329. [DOI: 10.1007/978-1-59745-148-2_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS; Cancer and Leukemia Group B. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 2011;117:2620-8. [PMID: 21656739 DOI: 10.1002/cncr.25742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
118 Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008;49:1498-505. [PMID: 18703606 DOI: 10.2967/jnumed.108.051771] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
119 Joensuu TK, Kiviluoto T, Kärkkäinen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;60:444-452. [PMID: 15380578 DOI: 10.1016/j.ijrobp.2004.03.026] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
120 Ohkawa K, Katayama K, Ikezawa K, Kawaguchi T, Tamai C, Imanaka K, Uehara H, Gotoh K, Takahashi H, Yamada T, Ohigashi H, Nishiyama K, Ishikawa O. Prior splenic irradiation reduces hematologic adverse events during chemotherapy in pancreatic tail cancer: a report of a patient with liver cirrhosis. Clin J Gastroenterol 2010;3:337-42. [PMID: 26190493 DOI: 10.1007/s12328-010-0185-6] [Reference Citation Analysis]
121 McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol. 2001;11:270-280. [PMID: 11677652 DOI: 10.1053/srao.2001.26002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
122 Yeo CJ, Cameron JL. Pancreatic cancer. Current Problems in Surgery 1999;36:57-152. [DOI: 10.1016/s0011-3840(99)80805-3] [Cited by in Crossref: 35] [Article Influence: 1.5] [Reference Citation Analysis]
123 Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics 2003;55:144-53. [DOI: 10.1016/s0360-3016(02)03818-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
124 Halim AA, Wahba HA, El-Hadaad HA, Abo-Elyazeed A. Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study. Med Oncol 2012;29:279-84. [PMID: 21279703 DOI: 10.1007/s12032-010-9811-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
125 DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999;117:1464-1484. [PMID: 10579989 DOI: 10.1016/s0016-5085(99)70298-2] [Cited by in Crossref: 255] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
126 Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13:13-21. [PMID: 12520460 DOI: 10.1053/srao.2003.50002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 9.4] [Reference Citation Analysis]
127 Muler JH, Mcginn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM. Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer. JCO 2004;22:238-43. [DOI: 10.1200/jco.2004.03.129] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
128 Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, Mcginn CJ. Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial. JCO 2008;26:942-7. [DOI: 10.1200/jco.2007.13.9014] [Cited by in Crossref: 116] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
129 Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem J. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 2010;116:5200-6. [DOI: 10.1002/cncr.25303] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
130 Symon Z, Davis M, McGinn CJ, Zalupski MM, Lawrence TS. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys. 2002;53:140-145. [PMID: 12007952 DOI: 10.1016/S0360-3016(01)02790-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
131 Pauwels B, Korst AE, Lambrechts HA, Pattyn GG, de Pooter CM, Lardon F, Vermorken JB. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 2006;58:219-28. [PMID: 16331496 DOI: 10.1007/s00280-005-0158-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
132 Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol. 2011;34:460-465. [PMID: 20881474 DOI: 10.1097/coc.0b013e3181e9c103] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
133 Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB, Talamonti MS. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;80:476-82. [PMID: 20598452 DOI: 10.1016/j.ijrobp.2010.02.030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
134 van Bree C, Rodermond HM, de Vos J, Haveman J, Franken NA. Mismatch repair proficiency is not required for radioenhancement by gemcitabine. Int J Radiat Oncol Biol Phys 2005;62:1504-9. [PMID: 15925456 DOI: 10.1016/j.ijrobp.2005.04.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
135 Marsh Rde W, George T. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Curr Gastroenterol Rep 2006;8:111-20. [PMID: 16533473 DOI: 10.1007/s11894-006-0006-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
136 Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-9. [PMID: 11157033 DOI: 10.1200/JCO.2001.19.3.792] [Cited by in Crossref: 111] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
137 Bachir BG, Souhami L, Mansure JJ, Cury F, Vanhuyse M, Brimo F, Aprikian AG, Tanguay S, Sturgeon J, Kassouf W. Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer. Bladder Cancer 2017;3:105-12. [PMID: 28516155 DOI: 10.3233/BLC-160090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
138 Oh KS, Soto DE, Smith DC, Montie JE, Lee CT, Sandler HM. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2009;74:511-7. [PMID: 18977098 DOI: 10.1016/j.ijrobp.2008.08.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
139 Morgan MA, Parsels LA, Maybaum J, Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 2008;14:6744-50. [PMID: 18980967 DOI: 10.1158/1078-0432.CCR-08-1032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
140 Mierzwa ML, Nyati MK, Morgan MA, Lawrence TS. Recent advances in combined modality therapy. Oncologist 2010;15:372-81. [PMID: 20413642 DOI: 10.1634/theoncologist.2009-S105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
141 Kaiser A, Budach V. Neoadjuvant and adjuvant strategies for chemoradiation. Recent Results Cancer Res 2008;177:65-77. [PMID: 18084949 DOI: 10.1007/978-3-540-71279-4_9] [Reference Citation Analysis]
142 Pauwels B, Korst A, de Pooter C, Lambrechts H, Pattyn G, Lardon F, Vermorken J. The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. European Journal of Cancer 2003;39:838-46. [DOI: 10.1016/s0959-8049(03)00002-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
143 Sakata K, Someya M, Matsumoto Y, Tauchi H, Kai M, Toyota M, Takagi M, Hareyama M, Fukushima M. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci 2011;102:1712-6. [PMID: 21668582 DOI: 10.1111/j.1349-7006.2011.02004.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
144 Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs 1996;14:257-63. [PMID: 8958180 DOI: 10.1007/BF00194528] [Cited by in Crossref: 63] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
145 Nitsche M, Christiansen H, Hermann RM, Lucke EM, Peters K, Rave-Frank M, Schmidberger H, Pradier O. The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro. Int J Radiat Biol 2008;84:643-57. [PMID: 18661380 DOI: 10.1080/09553000802241754] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
146 Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey J, Janjan NA. Combining Gemcitabine With Radiation in Pancreatic Cancer: Understanding Important Variables Influencing the Therapeutic Index. Seminars in Oncology 2001;28:25-33. [DOI: 10.1016/s0093-7754(01)80006-3] [Cited by in Crossref: 26] [Article Influence: 1.2] [Reference Citation Analysis]
147 Hiroshima Y, Fukumitsu N, Saito T, Numajiri H, Murofushi KN, Ohnishi K, Nonaka T, Ishikawa H, Okumura T, Sakurai H. Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. Radiother Oncol 2019;136:37-43. [PMID: 31015127 DOI: 10.1016/j.radonc.2019.03.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
148 Russo S, Butler J, Ove R, Blackstock AW. Locally advanced pancreatic cancer: a review. Semin Oncol 2007;34:327-34. [PMID: 17674961 DOI: 10.1053/j.seminoncol.2007.05.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
149 Takahashi H, Ohigashi H, Ishikawa O, Gotoh K, Yamada T, Nagata S, Tomita Y, Eguchi H, Doki Y, Yano M. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102. [PMID: 22123160 DOI: 10.1097/sla.0b013e31823d813c] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 7.9] [Reference Citation Analysis]
150 Murata Y, Hamada T, Kishiwada M, Ohsawa I, Mizuno S, Usui M, Sakurai H, Tabata M, Ii N, Inoue H, Shiraishi T, Isaji S. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J Hepatobiliary Pancreat Sci 2012;19:413-25. [PMID: 21898089 DOI: 10.1007/s00534-011-0440-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
151 Yeo T, Kintner J, Armand R, Perez R, Lewis L. Sublethal concentrations of gemcitabine (2′,2′-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells. Hum Exp Toxicol 2007;26:911-21. [DOI: 10.1177/0960327107086513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 Fiore M, Trodella L, Valeri S, Borzomati D, Floreno B, Ippolito E, Trecca P, Trodella LE, D'Angelillo RM, Ramella S, Coppola R. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. Radiat Oncol 2015;10:255. [PMID: 26670587 DOI: 10.1186/s13014-015-0564-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
153 Budiharto T, Haustermans K, Van Cutsem E, Van Steenbergen W, Topal B, Aerts R, Ectors N, Bielen D, Vanbeckevoort D, Goethals L. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma. Radiat Oncol. 2008;3:30. [PMID: 18808686 DOI: 10.1186/1748-717X-3-30] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
154 Alberts SR, Gores GJ, Kim GP, Roberts LR, Kendrick ML, Rosen CB, Chari ST, Martenson JA. Treatment Options for Hepatobiliary and Pancreatic Cancer. Mayo Clinic Proceedings 2007;82:628-37. [DOI: 10.4065/82.5.628] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
155 Urbanic JJ, Lally B, Blackstock AW. "The best-laid plans ... often go awry ...". J Thorac Oncol 2009;4:783-4. [PMID: 19550240 DOI: 10.1097/JTO.0b013e3181a99bf0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
156 Huang Y, Wu Y, Xie S, Yang J, Huang Y, Liao R. Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial: . Chinese Medical Journal 2007;120:458-62. [DOI: 10.1097/00029330-200703020-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
157 Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, Pond GR, Hedley D, Wong S, Townsley C, Brezden-masley C, Moore M. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A phase I-II study. International Journal of Radiation Oncology*Biology*Physics 2007;67:1027-36. [DOI: 10.1016/j.ijrobp.2006.10.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
158 Oya N, Shibuya K, Sakamoto T, Mizowaki T, Doi R, Fujimoto K, Imamura M, Nagata Y, Hiraoka M. Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine. Pancreatology 2006;6:109-16. [PMID: 16327288 DOI: 10.1159/000090030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
159 Takeda Y, Nakamori S, Eguchi H, Kobayashi S, Marubashi S, Tanemura M, Konishi K, Yoshioka Y, Umeshita K, Mori M. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Jpn J Clin Oncol. 2014;44:1172-1180. [PMID: 25425728 DOI: 10.1093/jjco/hyu143] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
160 Seong J, Kim SH, Suh CO. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma. J Gastroenterol Hepatol. 2001;16:883-889. [PMID: 11555102 DOI: 10.1046/j.1440-1746.2001.02533.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
161 Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist. 2006;11:612-623. [PMID: 16794240 DOI: 10.1634/theoncologist.11-6-612] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
162 Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-91. [DOI: 10.1002/(sici)1097-0142(19970715)80:2<286::aid-cncr17>3.0.co;2-q] [Cited by in Crossref: 135] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
163 Peters G, van der Wilt C, van Moorsel C, Kroep J, Bergman A, Ackland S. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacology & Therapeutics 2000;87:227-53. [DOI: 10.1016/s0163-7258(00)00086-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 56] [Article Influence: 8.5] [Reference Citation Analysis]
164 Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-josef E. Radiation Therapy With Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 2012;83:921-6. [DOI: 10.1016/j.ijrobp.2011.08.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
165 Hennequin C, Favaudon V. Quelles nouvelles drogues peut-on utiliser dans les associations chimioradiothérapie ? Cancer/Radiothérapie 1999;3:28s-41s. [DOI: 10.1016/s1278-3218(00)88220-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
166 Murata Y, Mizuno S, Kishiwada M, Uchida K, Noguchi D, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Tanemura A, Kuriyama N, Sakurai H, Isaji S. Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma. Pancreatology 2021:S1424-3903(21)00534-2. [PMID: 34452821 DOI: 10.1016/j.pan.2021.08.011] [Reference Citation Analysis]
167 Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, Margaritora S, Cesario A, D'Angelillo RM, Gualano G, Ramella S, Galetta D, Cellini N. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002;20:804-10. [PMID: 11821464 DOI: 10.1200/JCO.2002.20.3.804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
168 Van Laethem J, Demols A, Gay F, Closon M, Collette M, Polus M, Houbiers G, Gastelblum P, Gelin M, Houtte PV, Closset J. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. International Journal of Radiation Oncology*Biology*Physics 2003;56:974-80. [DOI: 10.1016/s0360-3016(03)00164-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
169 Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27:2269-2277. [PMID: 19307501 DOI: 10.1200/jco.2008.19.7921] [Cited by in Crossref: 174] [Cited by in F6Publishing: 60] [Article Influence: 13.4] [Reference Citation Analysis]
170 Trodella L, D'angelillo R, Ramella S, Cellini F, Ciresa M, Cesario A, Granone P. Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine. Annals of Oncology 2006;17:v52-4. [DOI: 10.1093/annonc/mdj950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
171 Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman K, Ang K. Maximizing therapeutic gain with gemcitabine and fractionated radiation. International Journal of Radiation Oncology*Biology*Physics 1999;44:1125-35. [DOI: 10.1016/s0360-3016(99)00134-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
172 Mizumoto K, Qian L, Zhang L, Nagai E, Kura S, Tanaka M. A Nitroimidazole Derivative, PR-350, Enhances the Killing of Pancreatic Cancer Cells Exposed to High-dose Irradiation under Hypoxia. JRR;43:43-43. [DOI: 10.1269/jrr.43.43] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
173 Sainato A, Montrone S, Pasqualetti F, Coppola M, Cernusco NLV, Panichi M, Gonnelli A, Vasile E, Morganti R, Falcone A, Boggi U, Paiar F. Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience. Tumori 2017;103:577-82. [PMID: 28708229 DOI: 10.5301/tj.5000664] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
174 Cardillo TM, Blumenthal R, Ying Z, Gold DV. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer. Int J Cancer 2002;97:386-92. [DOI: 10.1002/ijc.1613] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
175 Grégoire V, Beauduin M, Rosier JF, De Coster B, Bruniaux M, Octave-Prignot M, Scalliet P. Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells. Br J Cancer 1997;76:1315-21. [PMID: 9374377 DOI: 10.1038/bjc.1997.554] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
176 Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766-772. [PMID: 13129554 DOI: 10.1016/s1091-255x(03)00113-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
177 Sangar VK, Mcbain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, Clarke NW, Cowan RA. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. International Journal of Radiation Oncology*Biology*Physics 2005;61:420-5. [DOI: 10.1016/j.ijrobp.2004.05.074] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
178 Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiat Oncol. 2013;8:44. [PMID: 23452509 DOI: 10.1186/1748-717X-8-44] [Cited by in Crossref: 72] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
179 Rosenberg L, Lipsett M. Biotherapeutic approaches to pancreatic cancer. Expert Opin Biol Ther. 2003;3:319-337. [PMID: 12662145 DOI: 10.1517/14712598.3.2.319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
180 Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487-3495. [PMID: 18640929 DOI: 10.1200/jco.2007.15.8642] [Cited by in Crossref: 351] [Cited by in F6Publishing: 153] [Article Influence: 25.1] [Reference Citation Analysis]
181 Belka C, Nieder C, Molls M. Biological Basis of Combined Radio- and Chemotherapy. In: Brown JM, Mehta MP, Nieder C, editors. Multimodal Concepts for Integration of Cytotoxic Drugs. Berlin/Heidelberg: Springer-Verlag; 2006. pp. 3-17. [DOI: 10.1007/3-540-35662-2_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
182 Sangar VK, Cowan R, Margison GP, Hendry JH, Clarke NW. An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines. Br J Cancer 2004;90:542-8. [PMID: 14735206 DOI: 10.1038/sj.bjc.6601538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
183 Hoang B, Reilly RM, Allen C. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules 2012;13:455-65. [PMID: 22191486 DOI: 10.1021/bm201479t] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
184 Grégoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave-Prignot M, Scalliet P. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro. Radiother Oncol 2002;63:329-38. [PMID: 12142097 DOI: 10.1016/s0167-8140(02)00106-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
185 Mose S, Class R, Weber HW, Rahn A, Brady LW, Böttcher HD. Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 2003;26:60-9. [PMID: 12576927 DOI: 10.1097/00000421-200302000-00013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
186 Robinson BW, Ostruszka L, Im MM, Shewach DS. Promising combination therapies with gemcitabine. Seminars in Oncology 2004;31:2-12. [DOI: 10.1053/j.seminoncol.2004.03.021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
187 Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs. 2000;59:1071-1089. [PMID: 10852640 DOI: 10.2165/00003495-200059050-00004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 2.6] [Reference Citation Analysis]
188 Nishida T, Tsutsui S, Yamamoto K, Konishi K, Hayashi Y, Iijima H, Tsujii M, Takeda Y, Kitagawa T, Yoshioka Y, Inoue T, Hayashi N. Phase I trial of gemcitabine dose escalation with concurrent radiotherapy for patients with locally advanced pancreatic cancer. Pancreatology 2010;10:60-5. [PMID: 20332663 DOI: 10.1159/000231978] [Reference Citation Analysis]
189 Mcginn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: Current status of clinical trials. International Journal of Radiation Oncology*Biology*Physics 2003;56:10-5. [DOI: 10.1016/s0360-3016(03)00449-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
190 Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, Park SW. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:535-541. [PMID: 18828020 DOI: 10.1007/s00280-008-0836-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
191 Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84:1166-1171. [PMID: 22543215 DOI: 10.1016/j.ijrobp.2012.02.051] [Cited by in Crossref: 140] [Cited by in F6Publishing: 124] [Article Influence: 14.0] [Reference Citation Analysis]
192 Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, Robertson JM. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Int J Radiat Oncol Biol Phys 2012;83:e331-5. [PMID: 22420967 DOI: 10.1016/j.ijrobp.2012.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
193 Hamzian N, Hashemi M, Ghorbani M, Aledavood SA, Ramezani M, Bahreyni Toosi MH. In-vitro Study of Multifunctional PLGA-SPION Nanoparticles Loaded with Gemcitabine as Radiosensitizer Used in Radiotherapy. Iran J Pharm Res 2019;18:1694-703. [PMID: 32184839 DOI: 10.22037/ijpr.2019.14050.12131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Murphy JD, Lucas DR, Somnay YR, Hamstra DA, Ray ME. Gemcitabine-mediated radiosensitization of human soft tissue sarcoma. Transl Oncol 2008;1:50-6. [PMID: 18607508 DOI: 10.1593/tlo.07121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
195 Yang S, Zhang X, Jiang M, Ashamalla H, Rafla S. Unusual radiation response of gemcitabine-treated HeLa cells: reduced and enhanced survival. Cancer Letters 2002;187:179-83. [DOI: 10.1016/s0304-3835(02)00454-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
196 Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys 1998;41:875-82. [PMID: 9652852 DOI: 10.1016/s0360-3016(98)00105-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
197 Takahashi H, Akita H, Ioka T, Wada H, Tomokoni A, Asukai K, Ohue M, Yano M, Ishikawa O. Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer. Pancreas 2018;47:1135-41. [PMID: 30134354 DOI: 10.1097/MPA.0000000000001140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
198 Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7. [PMID: 15226765 DOI: 10.1038/sj.bjc.6602001] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 4.3] [Reference Citation Analysis]
199 Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalcberg JR, Leong T. A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. Br J Cancer 2009;100:37-43. [PMID: 19088724 DOI: 10.1038/sj.bjc.6604827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
200 Zarbá J, Jaremtchuk A, Gonzalez Jazey P, Keropian M, Castagnino R, Mina C, Arroyo G. A phase I–II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma. Annals of Oncology 2003;14:1285-90. [DOI: 10.1093/annonc/mdg345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
201 Halim A, Wahba H. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC. Med Oncol 2012;29:454-8. [PMID: 21350875 DOI: 10.1007/s12032-011-9868-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
202 Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol 2008;35:673-8. [PMID: 18678352 DOI: 10.1016/j.nucmedbio.2008.05.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
203 Blackstock AW, Ho C, Butler J, Fletcher-steede J, Case LD, Hinson W, Miller AA. Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and Dose-Escalated Thoracic Radiation in Patients with Stage III A/B Non-small Cell Lung Cancer: . Journal of Thoracic Oncology 2006;1:434-40. [DOI: 10.1097/01243894-200606000-00010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
204 Mcginn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002;95:933-40. [DOI: 10.1002/cncr.10754] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
205 Aparicio J, García-Mora C, Martín M, Petriz ML, Feliu J, Sánchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. PLoS One 2014;9:e82209. [PMID: 24416138 DOI: 10.1371/journal.pone.0082209] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]